M.G. Schlieman
Impact in
-
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
-
- Cancer Genomics and Diagnostics
Papers in
-
- Ubiquitin and proteasome pathways 3
- Glycosylation and Glycoproteins Research 2
- Cell death mechanisms and regulation 2
- PI3K/AKT/mTOR signaling in cancer 2
- Oncology 2
- Peptidase Inhibition and Analysis 2
- Co-authors
- Richard J. Bold (6 shared papers)Bridget N. Fahy (2 shared papers)Laurel Beckett (1 shared paper)Rajendra Ramsamooj (1 shared paper)S. Virudachalam (4 shared papers)Subbulakshmi Virudachalam (1 shared paper)Melinda M. Mortenson (4 shared papers)Joseph M. Galante (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)British Journal of Cancer (2 papers)Journal of Surgical Research (2 papers)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- United States
In The Last Decade
M.G. Schlieman
7 papers receiving 423 citations
Peers
Comparison fields: 5 of 60
- Oncology 177
- Cancer Research 76
- Molecular Biology 258
- Toxicology 10
- Pathology and Forensic Medicine 48
Countries citing papers authored by M.G. Schlieman
This map shows the geographic impact of M.G. Schlieman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.G. Schlieman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.G. Schlieman more than expected).
Fields of papers citing papers by M.G. Schlieman
This network shows the impact of papers produced by M.G. Schlieman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.G. Schlieman. The network helps show where M.G. Schlieman may publish in the future.
Co-authors
The 11 scholars most cited alongside M.G. Schlieman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 210 | |
| 2 | 2003 | 101 | |
| 3 | 2004 | 90 | |
| 4 | 2003 | 14 | |
| 5 | 2004 | 11 | |
| 6 | 2004 | 2 | |
| 7 | 2004 | 2 |
About M.G. Schlieman
M.G. Schlieman is a scholar working on Molecular Biology, Oncology, Genetics, Pathology and Forensic Medicine and Hematology, having authored 7 papers that have together received 430 indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (3 papers), Glycosylation and Glycoproteins Research (2 papers), Cell death mechanisms and regulation (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Peptidase Inhibition and Analysis (2 papers), Cancer Mechanisms and Therapy (1 paper), Chronic Lymphocytic Leukemia Research (1 paper) and NF-κB Signaling Pathways (1 paper). The work is most often cited by research in Oncology (177 citations), Cancer Research (76 citations), Molecular Biology (258 citations), Toxicology (10 citations) and Pathology and Forensic Medicine (48 citations). M.G. Schlieman has collaborated with scholars based in United States. Frequent co-authors include Richard J. Bold, Bridget N. Fahy, Laurel Beckett, Rajendra Ramsamooj, S. Virudachalam, Subbulakshmi Virudachalam, Melinda M. Mortenson, Joseph M. Galante, Angela M. Davies and Primo N. Lara. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Journal of Surgical Research and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.